Home > > > > > Report Detail

Aplastic Anemia - Pipeline Review, H2 2020

Publisher Name :
Date: 30-Nov-2020
No. of pages: 122
Inquire Before Buying

Aplastic Anemia - Pipeline Review, H2 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia - Pipeline Review, H2 2020, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape.

Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Aplastic Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 4, 2, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Aplastic Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Aplastic Anemia (Hematological Disorders).

- The pipeline guide reviews pipeline therapeutics for Aplastic Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Aplastic Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Aplastic Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Aplastic Anemia (Hematological Disorders)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Aplastic Anemia (Hematological Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Aplastic Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Aplastic Anemia - Pipeline Review, H2 2020

Table of Contents
Introduction
zAplastic Anemia - Overview
zAplastic Anemia - Therapeutics Development
zAplastic Anemia - Therapeutics Assessment
zAplastic Anemia - Companies Involved in Therapeutics Development
zAplastic Anemia - Drug Profiles
zAplastic Anemia - Dormant Projects
zAplastic Anemia - Discontinued Products
zAplastic Anemia - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Aplastic Anemia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Aplastic Anemia - Pipeline by Acceleron Pharma Inc, H2 2020
Aplastic Anemia - Pipeline by Amgen Inc, H2 2020
Aplastic Anemia - Pipeline by ASC Therapeutics Inc, H2 2020
Aplastic Anemia - Pipeline by BioLineRx Ltd, H2 2020
Aplastic Anemia - Pipeline by Cell Source Inc, H2 2020
Aplastic Anemia - Pipeline by Cellenkos Inc, H2 2020
Aplastic Anemia - Pipeline by Elixirgen Therapeutics LLC, H2 2020
Aplastic Anemia - Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
Aplastic Anemia - Pipeline by Gamida Cell Ltd, H2 2020
Aplastic Anemia - Dormant Projects, H2 2020
Aplastic Anemia - Discontinued Products, H2 2020

List of Figures
Number of Products under Development for Aplastic Anemia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
  • Global Fibrinogen Concentrate Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The Fibrinogen Concentrate market covers Human Fibrinogen Concentrate, Other, etc. The typical players include CSL Behring, LFB, Shanghai RAAS, Boya, Hualan Biological Engineering, etc. The global Fibrinogen Concentrate market was valued at US$ 796 million in 2023 and is anticipated to reach US$ 2207.6 million by 2030, witnessing a CAGR of 15.5% during The forecast period 2024-2030. The major producers in The industry are CSL Behring, LFB Group and Shanghai RAAS B......
  • Global Fibrinogen Concentrate Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 91
    According to our LPI (LP Information) latest study, the global Fibrinogen Concentrate market size was valued at US$ 778.7 million in 2023. With growing demand in downstream market, the Fibrinogen Concentrate is forecast to a readjusted size of US$ 2211.3 million by 2030 with a CAGR of 16.1% during review period. The research report highlights the growth potential of the global Fibrinogen Concentrate market. Fibrinogen Concentrate are expected to show stable growth in the future market. H......
  • Global Low Molecular Weight Heparin Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 124
    Market Overview of Global Low Molecular Weight Heparin market: According to our latest research, the global Low Molecular Weight Heparin market looks promising in the next 5 years. As of 2022, the global Low Molecular Weight Heparin market was estimated at USD 359.23 million, and it's anticipated to reach USD 601.59 million in 2028, with a CAGR of 8.97% during the forecast years. Low-molecular-weight heparin (LMWH) is a class of anticoagulant medications. They are used in the......
  • Global Anticoagulants Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 106
    According to our LPI (LP Information) latest study, the global Anticoagulants market size was valued at US$ 25390 million in 2023. With growing demand in downstream market, the Anticoagulants is forecast to a readjusted size of US$ 35420 million by 2030 with a CAGR of 4.9% during review period. The research report highlights the growth potential of the global Anticoagulants market. Anticoagulants are expected to show stable growth in the future market. However, product differentiation, r......
  • Global Injectable Anticoagulants Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 95
    According to our LPI (LP Information) latest study, the global Injectable Anticoagulants market size was valued at US$ 5959.5 million in 2023. With growing demand in downstream market, the Injectable Anticoagulants is forecast to a readjusted size of US$ 6929.9 million by 2030 with a CAGR of 2.2% during review period. The research report highlights the growth potential of the global Injectable Anticoagulants market. Injectable Anticoagulants are expected to show stable growth in the futu......
  • Global Low Molecular Weight Heparin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 88
    According to our LPI (LP Information) latest study, the global Low Molecular Weight Heparin market size was valued at US$ 331.2 million in 2023. With growing demand in downstream market, the Low Molecular Weight Heparin is forecast to a readjusted size of US$ 485.1 million by 2030 with a CAGR of 5.6% during review period. The research report highlights the growth potential of the global Low Molecular Weight Heparin market. Low Molecular Weight Heparin are expected to show stable growth i......
  • Global Heparin Sodium Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 132
    According to our LPI (LP Information) latest study, the global Heparin Sodium market size was valued at US$ 3301.4 million in 2023. With growing demand in downstream market, the Heparin Sodium is forecast to a readjusted size of US$ 5093.5 million by 2030 with a CAGR of 6.4% during review period. The research report highlights the growth potential of the global Heparin Sodium market. Heparin Sodium are expected to show stable growth in the future market. However, product differentiation,......
  • Global Intravenous Immunoglobulin (IVIg) Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 120
    According to our LPI (LP Information) latest study, the global Intravenous Immunoglobulin (IVIg) market size was valued at US$ 10090 million in 2023. With growing demand in downstream market, the Intravenous Immunoglobulin (IVIg) is forecast to a readjusted size of US$ 15290 million by 2030 with a CAGR of 6.1% during review period. The research report highlights the growth potential of the global Intravenous Immunoglobulin (IVIg) market. Intravenous Immunoglobulin (IVIg) are expected to ......
  • Global Heparin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 128
    According to our LPI (LP Information) latest study, the global Heparin market size was valued at US$ 2286.2 million in 2023. With growing demand in downstream market, the Heparin is forecast to a readjusted size of US$ 3831.5 million by 2030 with a CAGR of 7.7% during review period. The research report highlights the growth potential of the global Heparin market. Heparin are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply ......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs